This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
1,4-DMAA
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW HIGH
Same drug-tested ban exposure as 1,3-DMAA (WADA S6 covers structural analogs); FDA-illegal in supplements; sourcing reliability is **worse than 1,3-DMAA** because the molecule has no pharmaceutical pedigree, was first identified by analytical chemists *in finished pre-workouts* in 2017 as a banned-substance dodge by labs evading DMAA enforcement, and dose-per-serving in caught products ranged 21–94 mg — a >4× spread that confirms there is no good-manufacturing-practice path. There is zero published human PK or efficacy data for the 1,4 isomer specifically. For a 20yo MMA athlete pursuing competitive licensure, this is a hard skip on doping-policy grounds alone; the safety profile is even less characterized than parent 1,3-DMAA's already-thin record.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, MMA athlete (this archetype) | HARD SKIP | WADA-banned by class language; FDA-illegal as supplement; sourcing exclusively gray-market with no QC; cardiovascular cost real and possibly worse than 1,3-DMAA. Caffeine 100-200 mg + theanine + tyrosine PRN delivers better cognitive lift with full sourcing legitimacy. |
30-50, executive maintenance | SKIP | Same regulatory + cardiovascular + sourcing arguments; modafinil is the clean alternative for sustained cognitive lift. |
50+ | SKIP | Cardiovascular risk profile is wrong for the demographic. |
Drug-tested at any level (amateur, collegiate, WADA, employer, military) | HARD SKIP | WADA S6 catch-all language covers structural analogs; positive test = sanction. |
Untested + recreational stimulant interest | — | still SKIP. Cleaner analogs exist (caffeine, ephedrine in jurisdictions where legal, modafinil with Rx) with vastly better sourcing reliability. |
Anxiety-prone | HARD SKIP | Class-typical anxiogenic profile, no theanine-style buffer available. |
Combat sport (combat-sport context) | HARD SKIP | Sympathomimetic load impairs reaction-time consistency, masks fatigue signals, raises heat-stroke risk in hard training and cuts. |
- ★20-30, brain-priority, MMA athlete (this archetype)HARD SKIP
WADA-banned by class language; FDA-illegal as supplement; sourcing exclusively gray-market with no QC; cardiovascular cost real and possibly worse than 1,3-DMAA. Caffeine 100-200 mg + theanine + tyrosine PRN delivers better cognitive lift with full sourcing legitimacy.
- 30-50, executive maintenanceSKIP
Same regulatory + cardiovascular + sourcing arguments; modafinil is the clean alternative for sustained cognitive lift.
- 50+SKIP
Cardiovascular risk profile is wrong for the demographic.
- Drug-tested at any level (amateur, collegiate, WADA, employer, military)HARD SKIP
WADA S6 catch-all language covers structural analogs; positive test = sanction.
- Untested + recreational stimulant interest—
still SKIP. Cleaner analogs exist (caffeine, ephedrine in jurisdictions where legal, modafinil with Rx) with vastly better sourcing reliability.
- Anxiety-proneHARD SKIP
Class-typical anxiogenic profile, no theanine-style buffer available.
- Combat sport (combat-sport context)HARD SKIP
Sympathomimetic load impairs reaction-time consistency, masks fatigue signals, raises heat-stroke risk in hard training and cuts.
▸ Subjective experience (deep)
Reports are sparse and confounded (most products contain stim cocktails, not isolated 1,4-DMAA). The class profile to expect — extrapolating from 1,3-DMAA at 50-75 mg + structural arguments above:
- Onset: 30-60 min orally
- Peak: 1-3 hours
- Duration: 3-6 hours
- Dominant subjective: alertness + mild euphoria + focused drive, predominantly noradrenergic feel ("hard-edged" rather than "smooth")
- Peripheral: elevated HR (10-25 bpm), elevated BP (~10-20 mmHg systolic), peripheral vasoconstriction, cool extremities
- Cognitive: sustained attention on rote tasks; does not reliably improve fluid reasoning or executive function — this is the same pattern as 1,3-DMAA and the broader aliphatic-amine class
- Comedown: mild-to-moderate fatigue, possible headache from rebound vasodilation, no clean "reset"
▸ Tolerance + cycling deep dive
Class-typical tolerance to subjective effects develops within 7-14 days of daily dosing (analogous to 1,3-DMAA + ephedrine). Cardiovascular tolerance develops more slowly, meaning chronic users dose-escalate to maintain stim feel while accumulating progressively higher blood-pressure load — the classic recipe for the cerebral hemorrhage and cardiomyopathy outcomes.
Practical: there is no responsible cycling protocol for 1,4-DMAA. The compound is not sufficiently characterized to set on/off windows, and the doping-policy + FDA enforcement posture makes any chronic use a regulatory exposure.
▸ Stacking deep dive
Synergistic with
- None recommended. Stacking unstudied stimulants with anything is a gray-zone harm-multiplier.
Avoid stacking with
- Caffeine — additive cardiovascular load, additive anxiogenic potential
- Other sympathomimetics (ephedrine, synephrine, yohimbine, octopamine, octodrine, DMHA, 1,3-DMAA, 1,3-DMBA — most of which co-occur in the same pre-workout products as 1,4-DMAA, often undeclared)
- MAOIs — theoretical hypertensive crisis risk
- Amphetamines, methylphenidate, modafinil — additive cardiovascular load with no clean cognitive return
- SSRIs / SNRIs — theoretical serotonin syndrome risk despite weak SERT affinity, real noradrenergic-overload risk
- Hard training sessions, especially heat or competition — sympathomimetics impair thermoregulation and obscure cardiovascular warning signs
Neutral / safe co-administration
- N/A; the compound shouldn't be taken at all for the user archetype.
▸ Drug interactions deep dive
Not formally characterized for 1,4-DMAA. Class-extrapolated:
- MAOIs (non-selective): likely hypertensive crisis at recreational doses
- Tricyclic antidepressants: additive cardiovascular load
- Beta blockers: unopposed α-agonism could paradoxically worsen hypertension
- General anesthesia: sympathomimetic interactions during perioperative period
- Pregnancy / breastfeeding: contraindicated by class-default
▸ Pharmacogenomics
No published pharmacogenomic data. By analogy to 1,3-DMAA + amphetamine:
- CYP2D6 variants likely affect metabolic clearance (CYP2D6 is the dominant pathway for related aliphatic amines)
- ADRB1 / ADRB2 variants likely modulate cardiovascular response
- COMT Val/Val vs Met/Met likely modulates dopaminergic subjective response
None of this is actionable, because the molecule shouldn't be used.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Pre-workout supplement (gray market) | various Amazon / vendor-direct brands (rotating) | $30-60/canister | Low | Per-serving content varies 21-94 mg in seized products (Cohen 2018). Often co-formulated with octodrine, 1,3-DMAA, 1,3-DMBA, deterenol — typically without disclosure. FDA-illegal. |
| "Research chemical" supplier | small online vendors (e.g., kimerachems and similar) | $20-50/g | Very low | "Lab research only" disclaimer is a fig leaf — most product is sold to bodybuilders. No pharmaceutical-grade COA. |
| Pharmaceutical supply | None | N/A | N/A | The compound has never been pharmaceuticalized in any jurisdiction. |
| Compounding pharmacy | None | N/A | N/A | Not on any compounding bulk-substances list. |
For the user archetype: do not source 1,4-DMAA from any of these paths. The molecule offers nothing that caffeine + L-theanine (cleaner, well-studied, sourced reliably) doesn't deliver better, and accepting a regulatory + cardiovascular + sourcing risk for a strictly inferior alternative makes no sense.
▸ Biomarkers to track (deep)
If somehow being used (against the recommendation of this entry):
Baseline
- ECG (rule out structural cardiac abnormalities, prolonged QT)
- Resting BP + HR (3-day morning average)
- Echocardiogram for any user >40 or with cardiovascular risk factors
- Anxiety + sleep VAS for 7 days pre-dose
During use
- Daily home BP + HR pre-dose and 1-2 hours post-dose
- Weekly anxiety + sleep VAS
- Watch for chest pain, palpitations, severe headache, vision changes — discontinue immediately
Stop signs (immediate)
- Systolic BP >160 sustained, HR >110 resting, chest pain, severe headache, neurological symptoms, syncope, unexplained shortness of breath
▸ Controversies / open debates Live debate
1. "1,3-DMAA users report 1,4-DMAA feels cleaner / less harsh."
- Possibly true at the subjective level, but anecdotal reports don't survive selection-bias scrutiny — users who switched typically had access to higher-purity 1,4-DMAA from newer-generation labs that took analytical chemistry more seriously than the late-stage 1,3-DMAA suppliers post-FDA enforcement. The "cleaner feel" plausibly reflects fewer adulterants and not lower per-mg toxicity.
2. "FDA hasn't gone after 1,4-DMAA as aggressively as 1,3-DMAA — maybe it's in a regulatory gray zone."
- False reassurance. FDA's published warning-letter language and the 11th Circuit precedent both apply to 1,4-DMAA. The lower enforcement profile reflects the smaller market footprint, not regulatory tolerance. A regulatory action against 1,4-DMAA would proceed under the same legal framework as the 1,3 cases.
3. "WADA only lists methylhexanamine specifically — maybe 1,4 isn't covered."
- False. WADA S6 entries always include "and other substances with similar chemical structure or similar biological effects." That language has been used historically to cover positional isomers and structural analogs across multiple substance classes. 1,4-DMAA would be sanctioned under that catch-all in any positive-test scenario. Drug-tested athletes treat the whole isomer family as banned.
4. "There's no human PK study, but mechanistically it should work like 1,3-DMAA."
- Possibly, but extrapolating across positional isomers in the aliphatic amine class is risky — small structural changes have produced both potency loss (most cases) and unexpected toxicity (a few historical cases in related series). The honest read is that 1,4-DMAA's pharmacology is inferred but not measured, and using a molecule of inferred-not-measured pharmacology for cognitive/athletic enhancement is poor risk management.
5. "Cohen et al.'s detection studies are forensic, not pharmacological — does that really apply to user decision-making?"
- Yes, because Cohen's two key findings — (a) 1,4-DMAA is being added to commercial products at variable, high-spread doses (21-94 mg) without disclosure or QC, and (b) it is being co-formulated with up to four other experimental stimulants per product — directly determine the sourcing risk a user faces. Even a user who decides "the molecule is OK" cannot reliably get just the molecule in the supply chain that exists today.
▸ Verdict change log
- 2026-05-10 — Initial verdict: SKIP-FOR-NOW / HIGH CONFIDENCE. WADA-banned by class language, FDA-illegal as supplement, gray-market sourcing only, zero published human PK or efficacy data, plausibly less potent than the parent 1,3-DMAA at equal cardiovascular cost. For the user archetype (20yo MMA athlete, brain-priority, drug-tested-eligible) there is no scenario in which this molecule beats caffeine + theanine + tyrosine on any axis. Verdict would update only if (a) a legitimate regulated-pharmaceutical pathway opened up (extremely unlikely), or (b) competitive licensing requirements changed for the user (also unlikely).
▸ Open questions / gaps Open
- No human PK study for 1,4-DMAA specifically exists. A 25-50 mg single-dose PK + cardiovascular characterization in healthy volunteers (the equivalent of Schilling 2013 for 1,3-DMAA) would be the obvious starting point but is unlikely to ever be funded given the regulatory status.
- No target-receptor binding data. NET/DAT/SERT/TAAR1 affinities are inferred from class precedent.
- No published case reports of 1,4-DMAA-specific adverse events. Likely a reflection of under-detection — the analytical labs that screen for stimulants in adverse-event tox panels weren't routinely testing for 1,4-DMAA until after the Cohen 2018 paper put it on the screening menu.
- Whether 1,4-DMAA's actual potency is lower, equal, or higher than 1,3-DMAA's. Structural arguments suggest lower CNS potency at preserved peripheral cost; receptor binding data would settle it but doesn't exist.
- Whether 1,4-DMAA persists in marketplaces in 2026 or has been displaced by even-newer aliphatic amine analogs. OPSS warnings and Cohen's 2021 follow-up suggest persistence; updated 2024-2026 surveillance data would refine this.
References
Cohen PA, Travis JC, Keizers PHJ, Deuster P, Venhuis BJ. 2018 — Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol 56(6):421-426. PMID 29115866
landmark identification of 1,4-DMAA as an unauthorized supplement adulterant; per-serving range 21-94 mg.
View StudyCohen PA, Travis JC, Vanhee C, Ohana D, Venhuis BJ. 2021 — Nine prohibited stimulants found in sports and weight loss supplements. Clin Toxicol 59(11):975-981. PMID 33755516
confirms 1,4-DMAA persistence in U.S. supplements four years post-identification, often as part of multi-stimulant cocktails.
View StudySchilling BK, Hammond KG, Bloomer RJ, Presley CS, Yates CR. 2013 — Physiological and pharmacokinetic effects of oral 1,3-dimethylamylamine administration in men. BMC Pharmacol Toxicol 14:52. PMID 24090077
only published human PK study for the parent 1,3 isomer; 1,4-DMAA pharmacology is extrapolated from this work.
View StudyEliason MJ, Eichner A, Cancio A, Bestervelt L, Adams BD, Deuster PA. 2012 — Case reports: Death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA). Mil Med 177(12):1455-9. PMID 23397688
military-context cardiac arrest case reports that drove DoD's Operation Supplement Safety; cardiovascular risk relevant to the 1,4 isomer by class extrapolation.
View StudyPharmacokinetic and Toxicological Aspects of 1,3-Dimethylamylamine with Clinical and Forensic Relevance (MDPI 2023)
modern toxicology synthesis for the 1,3 isomer; 1,4-DMAA addressed by class extrapolation.
View StudyJAMA Internal Medicine 2013 — Availability of DMAA Supplements Despite US Food and Drug Administration Action
early documentation of marketplace persistence post-FDA action; predicted the analog-substitution pattern that produced 1,4-DMAA.
View StudyFDA — DMAA in Products Marketed as Dietary Supplements
FDA's central regulatory page on DMAA + analogues.
View SourceUnited States v. Hi-Tech Pharmaceuticals, Inc., 11th Cir. 2019 — Justia case page
the controlling federal appellate precedent; held DMAA is not a dietary ingredient under DSHEA. Logic applies to 1,4-DMAA isomer.
View SourceOPSS — DMAA: A prohibited stimulant
DoD Operation Supplement Safety summary covering DMAA + isomers.
View SourceWADA — 2026 Prohibited List
S6 stimulant category; methylhexanamine entry covers positional isomers via "similar chemical structure or similar biological effects" catch-all language.
View SourceUSADA — 2026 WADA Prohibited List Athlete Advisory
accessible summary of 2026 changes.
View SourceMethylhexanamine — Wikipedia
overview of 1,3-DMAA pharmaceutical history (Forthane/Eli Lilly), regulatory timeline, and structural family.
View Source1,4-Dimethylamylamine — Wikipedia
basic chemical identity for the 1,4 positional isomer; confirms it has never been pharmaceuticalized.
View SourcePubChem CID 34204 — 5-Methyl-2-hexylamine
formal chemical entry; CAS 28292-43-5, MW 115.22, formula C₇H₁₇N.
View SourceHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.